Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

(2016) M. Angela Aznar et al.   JOURNAL OF IMMUNOLOGY

Intralesional PV-10 for in-transit melanoma-A single-center experience

(2016) Jocelyn Lippey et al.   JOURNAL OF SURGICAL ONCOLOGY

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma

(2016) Abhijit Ray et al.   Oncotarget

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

(2015) Riccardo Danielli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy

(2014) Francesca Pretto et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses

(2014) B. Weide et al.   Cancer Immunology Research

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity

(2013) T Hemmerle et al.   BRITISH JOURNAL OF CANCER

Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia

(2013) K. L. Gutbrodt et al.   Science Translational Medicine

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

(2013) G. L. Poli et al.   Cancer Immunology Research

The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF

(2012) Kathrin Schwager et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses

(2011) Connie Jackaman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

(2011) Katharina Frey et al.   Integrative Biology

High response rate after intratumoral treatment with interleukin-2

(2010) Benjamin Weide et al.   CANCER

Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up

(2010) Benjamin Weide et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Immunocytokine F8-IL2 Improves the Therapeutic Performance of Sunitinib in a Mouse Model of Renal Cell Carcinoma

(2010) Katharina Frey et al.   JOURNAL OF UROLOGY

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

(2009) Christoph Schliemann et al.   LEUKEMIA RESEARCH

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculaturein vivo

(2008) Alessandra Villa et al.   INTERNATIONAL JOURNAL OF CANCER

Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation

(2008) Carla M.L. van Herpen et al.   INTERNATIONAL JOURNAL OF CANCER